Aleniglipron (Structure Therapeutics) -- Phase 2# Aleniglipron has produced the most competitive oral weight loss data to date: ACCESS: 11.3% placebo-adjusted weight loss at 36 weeks (120 mg) ACCESS II: 15.3% placebo-adjusted weight loss at 36 weeks (240 mg) Low-dose initiation (2.5 mg) significantly improved tolerability Phase 3 planned for mid-2026 At 36 weeks, aleniglipron's trajectory suggests it could approach injectable-level efficacy with longer treatment duration
Nausea, fatigue, and GI discomfort are common during initiation
Compounded versions, on the other hand, are produced in small batches and can have more variability in quality and formulation
Kind Regards After trying many M2 products over the years from other suppliers but found the side effects were really horrible which put me off, but with this purchase from Trutan Ive had little to no side effects, the occasional hot flush but no muscle stiffness or sickly feeling, definitely been the best so far- I will continue to use through the winter months
Stacks Well With Aminos, Peptides, and Electrolytes Its non-stimulant profile makes Tesofensine easy to stack with products like INTRA, BPC-157, or even ZMT for hormonal support during a deficit
However, the story is more nuanced than a simple yes or no
